跳至主要内容
临床试验/NCT03549195
NCT03549195Unknown不适用

Novel Tumor Targeted Fluorescent Peptide TMTP1-ICG Mapping in Laparoscopic Sentinel Micro-metastasis Lymph Node Detection in Cervical Cancer Patients

Huazhong University of Science and Technology1 个研究点 分布在 1 个国家目标入组 120 人开始时间: 2018年6月1日最近更新:
适应症

试验速览

阶段
不适用
入组人数
120
试验地点
1
主要终点
Detection rate of micro-metastasis sentinel lymph node

研究概览

简要总结

Investigators aimed to determine the validity of the investigator's novel tumor targeted fluorescent peptide TMTP1-ICG to increased accuracy of laparoscopic SLN mapping

研究设计

研究类型
Interventional
分配方式
Non Randomized
干预模型
Parallel
主要目的
Treatment
盲法
None

入排标准

年龄范围
30 Years 至 60 Years(Adult)
性别
Female
接受健康志愿者

入选标准

  • Without childbearing requirements at the time of consent.
  • FIGO stage IB1, IIA1 cervical cancer and is a candidate for laparoscopy intervention, with lymph node dissection being a part of the surgical plan.
  • Subject has provided written informed consent.

排除标准

  • Breast-feeding or pregnant.
  • Ongoing participation in another clinical trial with an investigational drug with 3 months
  • Own allergy towards ICG and/or alcohol
  • Diagnosis of bacterial vaginosis, fungal vaginitis, sexually transmitted diseases
  • Patients with cardiac dysfunction or hepatic insufficiency or renal insufficiency

结局指标

主要结局

Detection rate of micro-metastasis sentinel lymph node

时间窗: 7 days

Detection of micro-metastasis sentinel lymph node per patient

次要结局

  • Sensitivity(7 days)
  • Incidence of adverse events(7 days)
  • Specificity(7 days)

研究者

申办方类型
Other
责任方
Principal Investigator
主要研究者

Ding Ma

Director

Huazhong University of Science and Technology

研究点 (1)

Loading locations...

相似试验